Literature DB >> 20400051

Hypertension in pregnancy.

Marshall D Lindheimer1, Sandra J Taler, F Gary Cunningham.   

Abstract

Hypertension complicates 5% to 7% of all pregnancies. A subset of preeclampsia, characterized by new-onset hypertension, proteinuria, and multisystem involvement, is responsible for substantial maternal and fetal morbidity and is a marker for future cardiac and metabolic disease. This American Society of Hypertension (ASH) position paper summarizes the clinical spectrum of hypertension in pregnancy, focusing on preeclampsia. Recent research breakthroughs relating to etiology are briefly reviewed. Topics include classification of the different forms of hypertension during pregnancy, and status of the tests available to predict preeclampsia, and strategies to prevent preeclampsia and to manage this serious disease. The use of antihypertensive drugs in pregnancy, and the prevention and treatment of the convulsive phase of preeclampsia, eclampsia, with intravenous MgSO(4) is also highlighted. Of special note, this guideline article, specifically requested, reviewed, and accepted by ASH, includes solicited review advice from the American College of Obstetricians and Gynecologists. Copyright 2010 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID: 20400051     DOI: 10.1016/j.jash.2010.03.002

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  29 in total

1.  Clinical pearls in women's health.

Authors:  Lynne T Shuster; John B Bundrick; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

2.  Genetic variants, immune function, and risk of pre-eclampsia among American Indians.

Authors:  Lyle G Best; Melanie Nadeau; Kylie Davis; Felicia Lamb; Shellee Bercier; Cindy M Anderson
Journal:  Am J Reprod Immunol       Date:  2011-10-17       Impact factor: 3.886

3.  Increased protein-coding mutations in the mitochondrial genome of African American women with preeclampsia.

Authors:  David Ding; Nicole M Scott; Emma E Thompson; Tinnakorn Chaiworapongsa; Raul Torres; Christine Billstrand; Kathleen Murray; Phillip J Dexheimer; Mahmoud Ismail; Helen Kay; Shawn Levy; Roberto Romero; Marshall D Lindheimer; Dan L Nicolae; Carole Ober
Journal:  Reprod Sci       Date:  2012-08-17       Impact factor: 3.060

4.  Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia.

Authors:  Liqiong Wang; Tianli Yang; Yiling Ding; Yan Zhong; Ling Yu; Mei Peng
Journal:  Endocrine       Date:  2014-05-20       Impact factor: 3.633

5.  Pre-eclampsia and risk of subsequent hypertension: in an American Indian population.

Authors:  Lyle G Best; Laramie Lunday; Elisha Webster; Gilbert R Falcon; James R Beal
Journal:  Hypertens Pregnancy       Date:  2016-12-21       Impact factor: 2.108

Review 6.  The treatment of hypertension during pregnancy: when should blood pressure medications be started?

Authors:  Dawn C Scantlebury; Gary L Schwartz; Letitia A Acquah; Wendy M White; Marvin Moser; Vesna D Garovic
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

7.  Association of Carbon Monoxide exposure with blood pressure among pregnant women in rural Ghana: Evidence from GRAPHS.

Authors:  Ashlinn K Quinn; Kenneth Ayuurebobi Ae-Ngibise; Darby W Jack; Ellen Abrafi Boamah; Yeetey Enuameh; Mohammed Nuhu Mujtaba; Steven N Chillrud; Blair J Wylie; Seth Owusu-Agyei; Patrick L Kinney; Kwaku Poku Asante
Journal:  Int J Hyg Environ Health       Date:  2015-11-10       Impact factor: 5.840

8.  Inflammatory markers in the second trimester prior to clinical onset of preeclampsia, intrauterine growth restriction, and spontaneous preterm birth.

Authors:  Sofie Haedersdal; Jannie D Salvig; Martine Aabye; Christian W Thorball; Morten Ruhwald; Steen Ladelund; Jesper Eugen-Olsen; Niels J Secher
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

9.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Josef M Cortez; Athina Pappas; Adi L Tarca; Piya Chaemsaithong; Zhong Dong; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-08

10.  The maternal HLA-G 1597ΔC null mutation is associated with increased risk of pre-eclampsia and reduced HLA-G expression during pregnancy in African-American women.

Authors:  Dagan A Loisel; Christine Billstrand; Kathleen Murray; Kristen Patterson; Tinnakorn Chaiworapongsa; Roberto Romero; Carole Ober
Journal:  Mol Hum Reprod       Date:  2012-09-21       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.